A new study published in The Lancet Psychiatry critically examines the effectiveness of medicinal cannabis for mental health conditions, raising concerns about its widespread use and urging a reevaluation of regulatory practices.
A significant new study released on March 16, 2026, in The Lancet Psychiatry has cast doubt on the effectiveness of medicinal cannabis in treating mental health disorders, including anxiety, depression, and post-traumatic stress disorder (PTSD). The research, conducted by Dr. Jack Wilson and a team from the University of Sydney’s Matilda Centre, reviewed an extensive body of clinical evidence and concluded that there is insufficient support for the use of cannabis-based treatments for these conditions.
This analysis arrives at a moment when the demand for cannabinoid prescriptions is surging, particularly in Australia, where approvals have exceeded one million in recent years. This rapid increase in prescriptions has raised concerns that the pace of scientific investigation has not kept up with the growing acceptance of cannabis as a treatment option.
Rethinking Mental Health Treatments
Dr. Wilson highlighted that the implications of their findings could necessitate a reevaluation of how medicinal cannabis is utilized within mental health care frameworks. He remarked, “Though our paper didn’t specifically look at this, the routine use of medicinal cannabis could be doing more harm than good by worsening mental health outcomes, for example, a greater risk of psychotic symptoms and developing cannabis use disorder, and delaying the use of more effective treatments.” This caution signals the potential dangers of relying on cannabis without adequate medical oversight.
The study noted that over 700,000 Australians are using medicinal cannabis to manage more than 250 different conditions. However, the evidence supporting its efficacy is varied, with the review finding limited benefits for certain conditions like cannabis use disorder, autism, insomnia, and Tourette’s syndrome. Dr. Wilson cautioned that while some evidence of benefit exists, the overall quality of such evidence remains low. He stated, “In the absence of robust medical or counseling support, the use of medicinal cannabis in these cases is rarely justified,” emphasizing the need for careful consideration before prescribing cannabis.
Evaluating Substance-Use Disorders
The review also evaluated the effects of medicinal cannabis on substance-use disorders, revealing a complex relationship. While medicinal cannabis may assist in reducing cannabis dependence, it was found to exacerbate cravings for cocaine among individuals with cocaine-use disorder. Dr. Wilson noted, “Similar to how methadone is used to treat opioid-use disorder, cannabis medicines may form part of an effective treatment for those with a cannabis-use disorder. However, when medicinal cannabis was used to treat people with cocaine-use disorder, it increased their cravings.” This finding reinforces the notion that medicinal cannabis should not be considered a universal treatment option.
Regulatory Oversight and Medical Concerns
The steep rise in medicinal cannabis prescriptions has prompted concern from prominent medical organizations, including the Australian Medical Association (AMA) and the Pharmacy Guild of Australia. These groups have raised alarms regarding the insufficient regulation of cannabis-based products and the uncertainties surrounding their safety and efficacy. In response, the Therapeutic Goods Administration (TGA) has launched a review of medicinal cannabis regulations, which included the publication of over 500 submissions in February.
Dr. Wilson emphasized the importance of his study in aiding regulatory bodies and healthcare providers in making informed decisions regarding cannabis prescriptions. He stated, “Our study provides a comprehensive and independent assessment of the benefits and risks of cannabis medicines, which may support the TGA and clinicians to make evidence-based decisions, helping to ensure patients receive effective treatments while minimizing harm from ineffective or unsafe cannabis products.” This statement underscores the potential impact of the research on future policy-making and clinical practices.
Funding and Ethical Considerations
The research was funded by the National Health and Medical Research Council (NHMRC), and the authors have disclosed various affiliations and financial relationships that may influence their findings. Notably, Wayne Hall and Myfanwy Graham received consultation fees from the World Health Organization, while Hall has also been compensated for providing expert testimony on the risks associated with cannabis use. Graham serves on the Medicinal Cannabis Expert Working Group within the Australian Department of Health, Ageing and Disability and has received funding from the TGA for independent evidence reviews on medicinal cannabis. All other authors have declared no competing interests.
As discussions regarding the role of medicinal cannabis in healthcare continue to evolve, this study marks a critical juncture in understanding its implications for mental health treatment. The findings call for ongoing research and careful regulatory oversight to ensure that patients receive safe and effective treatments, while also highlighting the need for a balanced approach to the integration of cannabis in therapeutic contexts.
